Heptares Therapeutics
Welwyn Garden City
About Heptares Therapeutics
Heptares Therapeutics is a drug discovery company focused on novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable targets. The Company has developed a unique, transformational and proprietary technology for making purified, stabilised and functional GPCRs (known as StaRs, Stabilised Receptors), overcoming a major limiting factor to the development of new drugs targeting this group.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $50K – $100K
- Total funding: $61.5M
- Funding stage: M&A
- Last round: Series Unknown (May 2017)
- Website: soseiheptares.com
- Phone: +441707358628
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/heptares-therapeutics-18235 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.